Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Requena G, Ma L, Sturmer T, Layton JB, DiBello J. Association between an acute, drug-induced decrease in high-density lipoprotein cholesterol levels and risk of cardiovascular events. Clin Drug Invest. 2020 Aug;40:747-54. doi: 10.1007/s40261-020-00935-1
Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving Secukinumab. Clin Drug Invest. 2019 Dec;39(12):1205-12. doi: 10.1007/s40261-019-00856-8
Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer. 2018 Feb;26(2):539-48. doi: 10.1007/s00520-017-3863-9
Hauber AB, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D. Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. Support Care Cancer. 2018 Jan;26(1):251-60. doi: 10.1007/s00520-017-3841-2
Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D. "Same-day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016 Sep;24(9):3889-96. doi: 10.1007/s00520-016-3193-3
McKenna SP, Doward LC, Davey KM. The development and psychometric properties of the MSQOL: a migraine-specific quality-of-life instrument. Clin Drug Invest. 1998;15(5):413-23.